FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226340835> ?p ?o ?g. }

• W4226340835 abstract "Introduction Standard-of-care treatment for patients with newly diagnosed glioblastoma (GBM) after surgery or biopsy includes concurrent chemoradiation followed by maintenance temozolomide (TMZ) with tumor treating fields (TTFields). Preclinical studies suggest TTFields and radiotherapy work synergistically. We report the results of our trial evaluating the safety of TTFields used concurrently with chemoradiation. Methods This is a single-arm pilot study (clinicaltrials.gov Identifier: NCT03477110). Adult patients (age ≥ 18 years) with newly diagnosed glioblastoma and a Karnofsky performance score (KPS) of ≥ 60 were eligible. All patients received concurrent scalp-sparing radiation (60 Gy in 30 fractions) with TMZ (75 mg/m 2 daily) and TTFields (200 kHz). Maintenance therapy included TMZ and continuation of TTFields. Scalp-sparing radiation treatment was used to reduce radiation dermatitis. Radiation treatment was delivered through the TTFields arrays. The primary endpoint was safety and toxicity of tri-modality treatment within 30 days of completion of chemoradiation treatment. Results There were 30 patients enrolled, including 20 (66.7%) men and 10 (33.3%) women, with a median age of 58 years (range 19 to 77 years). Median KPS was 90 (range 70 to 100). A total of 12 (40%) patients received a gross total resection and 18 (60%) patients had a subtotal resection. A total of 12 (40%) patients had multifocal disease at presentation. There were 20 (66.7%) patients who had unmethylated O(6)-methylguanine-DNA-methyltransferase (MGMT) promotor status and 10 (33.3%) patients who had methylated MGMT promoter status. Median follow-up was 15.2 months (range 1.7 to 23.6 months). Skin adverse events were noted in 83.3% of patients, however, these were limited to Grade 1 or 2 events, which resolved spontaneously or with topical medications. The primary end point was met; no TTFields discontinuation occurred during the evaluation period due to high grade scalp toxicity. A total of 27 (90%) patients had progression, with a median progression-free survival (PFS) of 9.3 months (95% confidence interval (CI): 8.5-11.6 months). The 1-year progression-free survival was 23% (95% CI: 12%-45%). The median overall survival (OS) was 15.8 months (95% CI: 12.5 months-infinity). The 1-year overall survival was 66% (95% CI: 51%-86%). Conclusions Concurrent TTFields with scalp-sparing chemoradiation is a feasible and well-tolerated treatment option with limited toxicity. A phase 3, randomized clinical trial (EF-32, clinicaltrials.gov Identifier: NCT04471844) investigating the clinical benefit of concurrent TTFields with chemoradiation treatment is currently enrolling. Clinical Trial Registration Clinicaltrials.gov , identifier NCT03477110." @default.
• W4226340835 created "2022-05-05" @default.
• W4226340835 creator A5014352993 @default.
• W4226340835 creator A5017874214 @default.
• W4226340835 creator A5022471130 @default.
• W4226340835 creator A5026649515 @default.
• W4226340835 creator A5028702161 @default.
• W4226340835 creator A5032063105 @default.
• W4226340835 creator A5032466353 @default.
• W4226340835 creator A5036139080 @default.
• W4226340835 creator A5041267516 @default.
• W4226340835 creator A5045143686 @default.
• W4226340835 creator A5059909608 @default.
• W4226340835 creator A5061164194 @default.
• W4226340835 creator A5066158171 @default.
• W4226340835 creator A5068398880 @default.
• W4226340835 creator A5071629337 @default.
• W4226340835 creator A5086655595 @default.
• W4226340835 creator A5087888686 @default.
• W4226340835 creator A5088966716 @default.
• W4226340835 date "2022-04-29" @default.
• W4226340835 modified "2023-10-02" @default.
• W4226340835 title "Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma" @default.
• W4226340835 cites W2080954838 @default.
• W4226340835 cites W2096287682 @default.
• W4226340835 cites W2098950184 @default.
• W4226340835 cites W2113464761 @default.
• W4226340835 cites W2118841522 @default.
• W4226340835 cites W2124736921 @default.
• W4226340835 cites W2156330848 @default.
• W4226340835 cites W2156826863 @default.
• W4226340835 cites W2158681922 @default.
• W4226340835 cites W2162643152 @default.
• W4226340835 cites W2165871546 @default.
• W4226340835 cites W2205491921 @default.
• W4226340835 cites W2318481353 @default.
• W4226340835 cites W2340180801 @default.
• W4226340835 cites W2516444448 @default.
• W4226340835 cites W2778283729 @default.
• W4226340835 cites W2781425532 @default.
• W4226340835 cites W2792091224 @default.
• W4226340835 cites W2797234620 @default.
• W4226340835 cites W2895292947 @default.
• W4226340835 cites W2903060807 @default.
• W4226340835 cites W3012829181 @default.
• W4226340835 cites W3019001308 @default.
• W4226340835 cites W3032248100 @default.
• W4226340835 cites W3095618152 @default.
• W4226340835 cites W4242815556 @default.
• W4226340835 cites W4248428907 @default.
• W4226340835 doi "https://doi.org/10.3389/fonc.2022.896246" @default.
• W4226340835 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35574391" @default.
• W4226340835 hasPublicationYear "2022" @default.
• W4226340835 type Work @default.
• W4226340835 citedByCount "9" @default.
• W4226340835 countsByYear W42263408352022 @default.
• W4226340835 countsByYear W42263408352023 @default.
• W4226340835 crossrefType "journal-article" @default.
• W4226340835 hasAuthorship W4226340835A5014352993 @default.
• W4226340835 hasAuthorship W4226340835A5017874214 @default.
• W4226340835 hasAuthorship W4226340835A5022471130 @default.
• W4226340835 hasAuthorship W4226340835A5026649515 @default.
• W4226340835 hasAuthorship W4226340835A5028702161 @default.
• W4226340835 hasAuthorship W4226340835A5032063105 @default.
• W4226340835 hasAuthorship W4226340835A5032466353 @default.
• W4226340835 hasAuthorship W4226340835A5036139080 @default.
• W4226340835 hasAuthorship W4226340835A5041267516 @default.
• W4226340835 hasAuthorship W4226340835A5045143686 @default.
• W4226340835 hasAuthorship W4226340835A5059909608 @default.
• W4226340835 hasAuthorship W4226340835A5061164194 @default.
• W4226340835 hasAuthorship W4226340835A5066158171 @default.
• W4226340835 hasAuthorship W4226340835A5068398880 @default.
• W4226340835 hasAuthorship W4226340835A5071629337 @default.
• W4226340835 hasAuthorship W4226340835A5086655595 @default.
• W4226340835 hasAuthorship W4226340835A5087888686 @default.
• W4226340835 hasAuthorship W4226340835A5088966716 @default.
• W4226340835 hasBestOaLocation W42263408351 @default.
• W4226340835 hasConcept C126322002 @default.
• W4226340835 hasConcept C141071460 @default.
• W4226340835 hasConcept C143998085 @default.
• W4226340835 hasConcept C203092338 @default.
• W4226340835 hasConcept C2777389519 @default.
• W4226340835 hasConcept C2778496288 @default.
• W4226340835 hasConcept C2778515351 @default.
• W4226340835 hasConcept C509974204 @default.
• W4226340835 hasConcept C535046627 @default.
• W4226340835 hasConcept C71924100 @default.
• W4226340835 hasConceptScore W4226340835C126322002 @default.
• W4226340835 hasConceptScore W4226340835C141071460 @default.
• W4226340835 hasConceptScore W4226340835C143998085 @default.
• W4226340835 hasConceptScore W4226340835C203092338 @default.
• W4226340835 hasConceptScore W4226340835C2777389519 @default.
• W4226340835 hasConceptScore W4226340835C2778496288 @default.
• W4226340835 hasConceptScore W4226340835C2778515351 @default.
• W4226340835 hasConceptScore W4226340835C509974204 @default.
• W4226340835 hasConceptScore W4226340835C535046627 @default.
• W4226340835 hasConceptScore W4226340835C71924100 @default.
• W4226340835 hasFunder F4320313690 @default.
• W4226340835 hasLocation W42263408351 @default.
• W4226340835 hasLocation W42263408352 @default.

• next